Pharmacogenetic information derived from analysis of HLA alleles (Q37120841)

18 August 2017

1 reference

title

Pharmacogenetic information derived from analysis of HLA alleles (English)

1 reference

18 August 2017

3

Shinichi Oka

1 reference

18 August 2017

Hiroyuki Gatanaga

1

1 reference

18 August 2017

Haruhito Honda

series ordinal

2

1 reference

18 August 2017

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

207-214

1 reference

Clinical heterogeneity of drug hypersensitivity

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Familial occurrence of hypersensitivity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

How TCRs bind MHCs, peptides, and coreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Delayed Drug Hypersensitivity Reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Immune mechanisms in drug allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

The HIV-1 protease as a therapeutic target for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Epidemiological risk factors for hypersensitivity reactions to abacavir*

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

The influence of HLA genotype on AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Hepatotoxicity associated with nevirapine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Cutaneous disease and drug reactions in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Drug hypersensitivity in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Nevirapine-induced Stevens-Johnson syndrome in a mother and son.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Carbamazepine side effects in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Toxic epidermal necrolysis in a burns centre: a 6-year review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Pharmacogenetics and geographical ancestry: implications for drug development and global health

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Anaphylaxis after rechallenge with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.2.207

21 January 2018

Identifiers

DOI

10.2217/14622416.9.2.207

1 reference

18 August 2017

1 reference